Summary

Description

Summary

The purpose of this study is to investigate treatment with Nivolumab in combination with Trametinib with or without Ipilimumab in patients with previously treated cancer of the colon or rectum that has spread.

Official Title

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Participants with a condition requiring systemic treatment with either corticosteroids(> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration

History of interstitial lung disease or pneumonitis

Prior treatment with immune checkpoint inhibitors and MEK inhibitors

History of allergy to study treatments or any of its components of the study arm that participant is enrolling

Other protocol defined inclusion/exclusion criteria could apply

Locations

University of California San Francisco (UCSF)accepting new patientsSan FranciscoCalifornia94158United States